Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 16/20 | 0.67 |
| ▸ | MAOB | P27338 | 14/20 | 0.67 |
| ▸ | MAOA | P21397 | 13/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | MMP13 | P45452 | 1/20 | 0.54 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL239614 | 1.00 | KDM1A (0.67) | KDM1AMAOBMAOAKCNH2MMP13 | |
| SCHEMBL11888836 | 0.88 | KDM1A (0.63) | KDM1AMAOBMAOA | |
| SCHEMBL14714349 | 0.87 | KDM1A (0.62) | KDM1AMAOBMAOA | |
| SCHEMBL14714352 | 0.87 | KDM1A (0.62) | KDM1AMAOBMAOA | |
| SCHEMBL1667636 | 0.86 | KCNH2 (0.56) | KDM1AMAOBMAOAKCNH2 | |
| SCHEMBL1667637 | 0.86 | KCNH2 (0.56) | KDM1AMAOBMAOAKCNH2 | |
| SCHEMBL18923952 | 0.84 | KDM1A (0.64) | KDM1AMAOBMAOA | |
| SCHEMBL20724187 | 0.84 | KDM1A (0.64) | KDM1AMAOBMAOA | |
| SCHEMBL15091475 | 0.84 | KDM1A (0.64) | KDM1AMAOBMAOA | |
| SCHEMBL2755939 | 0.84 | KDM1A (0.64) | KDM1AMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3495349-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2023-06-28 | — | — | EP | disclosed |
| EP-3736265-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2020-11-11 | — | — | EP | disclosed |
| EP-2768805-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2020-03-25 | — | — | EP | disclosed |
| US-10329256-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS, S.A. (ES) | 2019-06-25 | — | — | US | disclosed |
| EP-3495349-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2019-06-12 | — | — | EP | disclosed |
| US-10233178-B2 | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use | ORYZON GENOMICS, S.A. (ES) | 2019-03-19 | — | — | US | disclosed |
| US-10202330-B2 | Lysine specific demethylase-1 inhibitors and their use | ORYZON GENOMICS, SA (ES) | 2019-02-12 | — | — | US | disclosed |
| EP-2776394-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2018-12-26 | — | — | EP | disclosed |
| US-20180354902-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2018-12-13 | — | — | US | disclosed |
| EP-3375775-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | Oryzon Genomics, S.A. (ES) | 2018-09-19 | — | — | EP | disclosed |
| EP-2560947-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | Oryzon Genomics, S.A. (ES) | 2013-02-27 | — | — | EP | disclosed |
| WO-2012013728-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | ORYZON GENOMICS S.A. (ES) | 2012-02-02 | — | — | WO | disclosed |
| US-20120004262-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | ORYZON GENOMICS, S.A. (ES) | 2012-01-05 | — | — | US | disclosed |
| EP-2389362-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | Oryzon Genomics, S.A. (ES) | 2011-11-30 | — | — | EP | disclosed |
| US-20110263604-A1 | Oxidase inhibitors and their use | ORYZON GENOMICS, S.A. (ES) | 2011-10-27 | — | — | US | disclosed |
| US-20110252680-A1 | Surface mounted frame arrangement | ROSE DISPLAYS, LTD | 2011-10-20 | — | — | US | disclosed |
| EP-2361242-A1 | OXIDASE INHIBITORS AND THEIR USE | Oryzon Genomics, S.A. (ES) | 2011-08-31 | — | — | EP | disclosed |
| US-20100324147-A1 | ARYLCYCLOPROPYLAMINES AND METHODS OF USE | DUKE UNIVERSITY | 2010-12-23 | — | — | US | disclosed |
| WO-2010084160-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | ORYZON GENOMICS S.A. (ES) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010043721-A1 | OXIDASE INHIBITORS AND THEIR USE | ORYZON GENOMICS, S.A. (ES) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180354902-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | KDM1A 2/4885MAOB 165/4885MAOA 143/4885 |
| US-10233178-B2 | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use | KDM6A, KDM1B, KDM1A | KDM1A 3/4885MAOB 66/4885MAOA 52/4885 |
| US-20110263604-A1 | Oxidase inhibitors and their use | MAOA, PNPO, MAOB | KDM1A 920/4885MAOB 3/4885MAOA 1/4885 |
| US-10202330-B2 | Lysine specific demethylase-1 inhibitors and their use | KDM1A, KDM1B, KDM3A | KDM1A 1/4885MAOB 219/4885MAOA 302/4885 |
| US-20100324147-A1 | ARYLCYCLOPROPYLAMINES AND METHODS OF USE | MAOA, MAOB, PNMT | KDM1A 14/4885MAOB 2/4885MAOA 1/4885 |
| US-20120004262-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | PNMT, ABCB1, SNCA | KDM1A 1515/4885MAOB 143/4885MAOA 80/4885 |
| US-10329256-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | KDM1A 2/4885MAOB 165/4885MAOA 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.